| Species |
Human |
| Protein Construction |
IL-21 (Gln32-Ser162)
Accession # Q9HBE4-1 |
|
| Purity |
> 95% as determined by Bis-Tris PAGE |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized IL-21, Human at 2μg/ml (100μl/well) on the plate can bind Human IL21R, hFc Tag. Test result was comparable to standard batch.
Measured by its ability to enhance IFNgamma secretion in NK92 human natural killer lymphoma cells. The ED50 for this effect is 13 ng/mL. Test result was comparable to standard batch. |
| Expression System |
E.coli |
| Theoretical Molecular Weight |
15.4 kDa |
| Apparent Molecular Weight |
The protein has a predicted MW of 15.4 kDa same as Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in 20mM NaAc, 150mM NaCl (pH 5.5). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in 20mM NaAc, 150mM NaCl (pH 5.5). |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Interleukin-21 (IL-21), produced predominantly by CD4 T cells and natural killer T (NKT) cells, is a newly discovered member of the common γ-chain family of cytokines. It has been implicated in many immunological processes and has been linked to autoimmune diseases, allergies and other inflammatory diseases. |
| Synonyms |
Interleukin-21; IL-21; Za11; CVID11 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
